{"disease":{"id":"familial-chylomicronemia-syndrome","name":"familial chylomicronemia syndrome"},"drugs":{"marketed":[{"drug_id":"plozasiran","indication_name":"familial chylomicronemia syndrome (FCS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Redemplo","generic_name":"PLOZASIRAN","company_name":"Arrowhead","drug_phase":"marketed","molecular_target":"apoC-III mRNA","drug_class":"APOC-III-directed RNA Interaction [EPC]","quality_score":47,"revenue":null,"mechanism":"Plozasiran reduces hepatic and serum apoC-III protein by degrading apoC-III mRNA via RNA interference, leading to increased clearance of serum triglycerides."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT03912181","title":"Medical Complications in Familial and Multifactorial Chylomicronaemia Syndromes","phase":"","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06471543","title":"Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":108,"lead_sponsor_name":"Ikaria Bioscience Pty Ltd","has_results":false},{"nct_id":"NCT02658175","title":"The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Akcea Therapeutics","has_results":true},{"nct_id":"NCT04568434","title":"A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":66,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04223908","title":"InFocus France Epidemiological Study of Health Burden in Major Hypertriglyceridemia","phase":"","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"New French Society of Atherosclerosis","has_results":false},{"nct_id":"NCT05902598","title":"A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Visirna Therapeutics HK Limited","has_results":true},{"nct_id":"NCT03360747","title":"Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Akcea Therapeutics","has_results":true},{"nct_id":"NCT06360237","title":"Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}